Physician profile
Douglas E Vogt
NPI 1669430070
$9,510.57
in general payments reported to CMS, 2019-2025
44 companies · $891 in 2025
The $891 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,166 · 2020: $1,106 · 2021: $1,509 · 2022: $1,698 · 2023: $1,379 · 2024: $1,762 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,031.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,942.40 | 2020-2025 | Rinvoq, Skyrizi, Humira |
| Lilly USA, LLC | $1,731.41 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $1,026.72 | 2019-2024 | Tremfya, Stelara, Remicade |
| Amgen INC. | $707.75 | 2019-2025 | Otezla, Otezla |
| Pfizer INC. | $547.89 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $522.33 | 2020-2025 | Dupixent, Libtayo |
| Merck Sharp & Dohme LLC | $381.15 | 2019-2022 | |
| Novo Nordisk INC | $281.76 | 2019-2022 | |
| Genzyme Corporation | $249.88 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $190.89 | 2019-2020 | |
| Almirall LLC | $189.76 | 2021-2025 | Klisyri, Seysara |
| Leo Pharma INC. | $159.61 | 2020-2025 | Adbry |
| Eisai INC. | $158.86 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $132.48 | 2019-2022 | |
| Glaxosmithkline, LLC. | $129.36 | 2019-2023 | Shingrix, Arexvy |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Vogt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.